Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
526 studies found for:    Open Studies | "Leukemia, Lymphoid"
Show Display Options
Rank Status Study
21 Recruiting Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Pentoxifylline Plus Chemotherapy;   Drug: Placebo Plus Chemotherapy
22 Recruiting CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphocytic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: Second generation CAR-T cells
23 Recruiting Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Biological: Alemtuzumab
24 Recruiting Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Third generation CAR-T cells
25 Recruiting Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Condition: Acute Lymphoid Leukemia
Interventions: Drug: Entospletinib;   Drug: VCR;   Drug: Dexamethasone;   Drug: CNS Prophylaxis
26 Recruiting A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: KTE-C19
27 Recruiting A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
28 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: ADCT-402
29 Recruiting A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: KTE-C19
30 Recruiting Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: liposomal cytarabine
31 Recruiting CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell;   Acute Lymphoblastic Leukaemia Recurrent
Intervention: Biological: CD19 CAR T cells
32 Recruiting Genetic Study of Familial Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia (ALL)
Intervention:
33 Recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GA101;   Drug: ibrutinib
34 Available Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: suspension of erythrocytes encapsulating L-asparaginase
35 Recruiting Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
Condition: Acute Lymphoblastic Leukemia Ph Positive
Interventions: Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine
36 Recruiting Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention: Drug: pyrimethamine
37 Recruiting A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Venetoclax
38 Recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Bcl-2 Inhibitor GDC-0199;   Biological: Obinutuzumab;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
39 Not yet recruiting A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
40 Recruiting Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
Condition: Lymphoblastic Leukemia, Acute, Childhood
Interventions: Drug: Allopurinol;   Drug: Standard treatment

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.